- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05953831
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy (REMOD-REVERT)
January 5, 2024 updated by: Cardior Pharmaceuticals GmbH
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess efficacy and safety of CDR132L on reverse remodeling.
In this study, patients with HFpEF (EF ≥50%) or HFmrEF (LVEF 45-49%) will be included.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
130
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cardior Clinical Team
- Phone Number: 30 +49511338599
- Email: clinical@cardior.de
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Main Inclusion Criteria:
- Provision of signed informed consent prior to any study-specific procedures.
- Male or female of non-childbearing potential patients age ≥40 and <85 years.
- Documented diagnosis of symptomatic heart failure (NYHA class II-IV) at enrollment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrollment with at least intermittent need for diuretic treatment.
- Ejection fraction ≥ 45% (determined by echocardiography at site laboratory)
- Increased intraventricular wall thickness (≥11 mm for female and ≥12 mm for male patients by echocardiography at site laboratory)
- NT-proBNP > 300 pg/ml (sinus rhythm); >900 pg/ml (atrial fibrillation at time of screening/inclusion or documented with the last 6 months)
- BMI between 22 kg/m² and 45 kg/m².
Main Exclusion Criteria:
- Hemoglobin A1C (A1C) ≥10.5%
- eGFR <35 mL/min/1.73m²
- Systolic blood pressure (BP) <90 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening.
- Systolic BP≥180 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening.
- Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
- Stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CDR132L 4.52 mg
Six times CDR132L 4.52 mg/kg body weight intravenous in single dose.
|
CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132).
miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5
Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
|
Placebo Comparator: Placebo
Six times Placebo intravenous in single dose.
|
Placebo to CDR132L
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular mass
Time Frame: 6 months
|
Left ventricular mass measured by cardiac magnetic resonance imaging (indexed to the height in meters raised to the power of 2)
|
6 months
|
Left atrial maximum volume
Time Frame: 6 months
|
Left atrial maximum volume (measured by cardiac magnetic resonance imaging in end systole(indexed to the height in meters raised to the power of 2))
|
6 months
|
Total cardiac extracellular volume
Time Frame: 6 months
|
Total cardiac extracellular volume (mL) measured by cardiac magnetic resonance imaging
|
6 months
|
Left atrial strain
Time Frame: 6 months
|
Left atrial strain measured by cardiac magnetic resonance imaging
|
6 months
|
Maximum left ventricular wall thickness
Time Frame: 6 months
|
Maximum left ventricular wall thickness measured by cardiac magnetic resonance imaging
|
6 months
|
Age-adjusted e' velocity
Time Frame: 6 months
|
Age-adjusted e' velocity measured by doppler echocardiography.
With e´velocity being the maximal velocity of mitral annular motion (E-wave).
|
6 months
|
Global longitudinal strain
Time Frame: 6 months
|
Global longitudinal strain measured by echocardiography
|
6 months
|
E/e'
Time Frame: 6 months
|
E/e' measured by doppler echocardiography to evaluate the LV filling pressure.
|
6 months
|
Concentration of N-terminal pro B-type natriuretic peptide
Time Frame: 6 months
|
Concentration measured as biomarker from blood samples.
|
6 months
|
Concentration of high-sensitivity cardiac troponin T
Time Frame: 6 months
|
Concentration measured as biomarker from blood samples.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
June 29, 2023
First Submitted That Met QC Criteria
July 18, 2023
First Posted (Actual)
July 20, 2023
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 5, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR132L-P2-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Preserved Ejection Fraction
-
University Hospital, AkershusNovartisActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionNorway
-
University of SienaEuropean Association of Cardiovascular ImagingActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionSpain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
-
Istituti Clinici Scientifici Maugeri SpARecruitingHeart Failure With Preserved Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
Milton S. Hershey Medical CenterWithdrawnHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Milton S. Hershey Medical CenterCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Zhijun SunEnrolling by invitationHeart Failure | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionChina
-
Corvia MedicalWithdrawnHeart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
-
Yale UniversityRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure NYHA Class IVUnited States
Clinical Trials on CDR132L
-
Cardior Pharmaceuticals GmbHActive, not recruitingMyocardial Infarction, Acute | Heart Failure, Left SidedNetherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
-
Cardior Pharmaceuticals GmbHCompleted